Cartesian Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 6.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 204.22M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyosi...